Summary
The effect of a new alpha-glucosidase inhibitor (BAY m 1099), a 1-deoxynojirimycin derivative, was studied in 10 black patients with Type II diabetes mellitus. It produced significant lowering of blood glucose concentration after standardized maize porridge meals. No significant untoward effects were noted. BAY m 1099 appears to offer potential benefit in the management of Type II diabetics, and more extensive clinical investigation is warranted.
This is a preview of subscription content, log in via an institution to check access.
References
Schmidt DD, Frommer W, Müller L et al. (1979) Glucosidase-Inhibitoren aus Bazillen. Naturwissenschaften 66: 584–585
Saunier B, Kilker RD, Tkacz JS et al. (1982) Inhibition of N-linked complex oligosaccharide synthesis by 1-deoxynojirimycin, an inhibitor of processing. J Biol Chem 23: 14155–14161
Joubert PH, Venter CP, Joubert HF, Hillebrand I (1985). The effect of a 1-deoxynojirimycin derivative on post-prandial blood glucose and insulin levels in healthy black and white volunteers. Eur J Clin Pharmacol 128: 705–708
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Joubert, P.H., Bam, W.J. & Manyane, N. Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics. Eur J Clin Pharmacol 30, 253–255 (1986). https://doi.org/10.1007/BF00614315
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00614315